Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory C Fanning

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
BMC Biotechnology|January 7, 2006
Design and cloning strategies for constructing shRNA expression vectorsGlen J McIntyre, Gregory C Fanning
Nature Reviews. Drug Discovery|August 29, 2019
Therapeutic strategies for hepatitis B virus infection: towards a cureGregory C Fanning, Fabien Zoulim, Jinlin Hou, et al.
Nature Reviews. Drug Discovery|January 9, 2020
Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cureGregory C Fanning, Fabien Zoulim, Jinlin Hou, et al.
BMC Molecular Biology|August 9, 2011
The effects of stem length and core placement on shRNA activityGlen J McIntyre, Yi-Hsin Yu, Mehnaaz Lomas, et al.
Genetic Vaccines and Therapy|April 19, 2011
A comparison of multiple shRNA expression methods for combinatorial RNAiGlen J McIntyre, Allison J Arndt, Kirsten M Gillespie, et al.
Gastroenterology|October 27, 2009
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patientsHenk W Reesink, Gregory C Fanning, Khalid Abou Farha, et al.
The Journal of Gene Medicine|January 19, 2005
Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patientsJanet L Macpherson, Maureen P Boyd, Allison J Arndt, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2012
TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverageBenoit Devogelaere, Jan Martin Berke, Leen Vijgen, et al.
Human Gene Therapy|March 17, 2004
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patientsRafael G Amado, Ronald T Mitsuyasu, Joseph D Rosenblatt, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435Oliver Lenz, Thierry Verbinnen, Tse-I Lin, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BMC Biotechnology|January 7, 2006
Design and cloning strategies for constructing shRNA expression vectorsGlen J McIntyre, Gregory C Fanning
Nature Reviews. Drug Discovery|August 29, 2019
Therapeutic strategies for hepatitis B virus infection: towards a cureGregory C Fanning, Fabien Zoulim, Jinlin Hou, et al.
Nature Reviews. Drug Discovery|January 9, 2020
Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cureGregory C Fanning, Fabien Zoulim, Jinlin Hou, et al.
BMC Molecular Biology|August 9, 2011
The effects of stem length and core placement on shRNA activityGlen J McIntyre, Yi-Hsin Yu, Mehnaaz Lomas, et al.
Genetic Vaccines and Therapy|April 19, 2011
A comparison of multiple shRNA expression methods for combinatorial RNAiGlen J McIntyre, Allison J Arndt, Kirsten M Gillespie, et al.
Gastroenterology|October 27, 2009
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patientsHenk W Reesink, Gregory C Fanning, Khalid Abou Farha, et al.
The Journal of Gene Medicine|January 19, 2005
Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patientsJanet L Macpherson, Maureen P Boyd, Allison J Arndt, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2012
TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverageBenoit Devogelaere, Jan Martin Berke, Leen Vijgen, et al.
Human Gene Therapy|March 17, 2004
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patientsRafael G Amado, Ronald T Mitsuyasu, Joseph D Rosenblatt, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435Oliver Lenz, Thierry Verbinnen, Tse-I Lin, et al.
Pageof 2